Media says Pfizer is also cashed up and looking at Australia for investment opportunities, so given this why do we need a Business development arm and the expense that goes with it.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%